Report Detail
Global Checkpoint Inhibitors for Treating Cancer Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
- RnM3185853 |
- 26 March, 2019 |
- Global |
- 108 Pages |
- GIR (Global Info Research) |
- Pharma & Healthcare
Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
Scope of the Report:
Those four kinds of checkpoint inhibitors are mainly used to treat melanoma, bladder cancer and others. In 2015, melanoma treatment consumed checkpoint inhibitors took a share of 80.53%. In 2016, melanoma treatment consumed checkpoint inhibitors will be 68153g. Bladder cancer treatment consumed checkpoint inhibitors will be 1978g.
Although YERVOY® (ipilimumab), OPDIVO® (nivolumab), KEYTRUDA® (pembrolizumab) and Tecentriq® (atezolizumab) are four indispensable medicines for cancer treatment, they also has many shortages. Firstly, they all have side effect for patient. Secondly, price of checkpoint inhibitors for treating cancer is too expensive. CTLA-4 inhibitors price is about 118.2 USD/mg in 2016. PD-1 inhibitors price is about 28.6 USD/mg in 2016. PD-L1 inhibitors price is about 30.5 USD/mg in 2016. For most patients, the price is unbearable.
The worldwide market for Checkpoint Inhibitors for Treating Cancer is expected to grow at a CAGR of roughly 28.0% over the next five years, will reach 20600 million US$ in 2024, from 4690 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Checkpoint Inhibitors for Treating Cancer in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Bristol-Myers Squibb(BMS)
Merck
Roche
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
Market Segment by Applications, can be divided into
Melanoma Treatment
Bladder Cancer Treatment
Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Checkpoint Inhibitors for Treating Cancer product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Checkpoint Inhibitors for Treating Cancer, with price, sales, revenue and global market share of Checkpoint Inhibitors for Treating Cancer in 2017 and 2018.
Chapter 3, the Checkpoint Inhibitors for Treating Cancer competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Checkpoint Inhibitors for Treating Cancer breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Checkpoint Inhibitors for Treating Cancer market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Checkpoint Inhibitors for Treating Cancer sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
- 1.1 Checkpoint Inhibitors for Treating Cancer Introduction
- 1.2 Market Analysis by Type
- 1.2.1 PD-1 Inhibitors
- 1.2.2 PD-L1 Inhibitors
- 1.2.3 CTLA-4 Inhibitors
- 1.3 Market Analysis by Applications
- 1.3.1 Melanoma Treatment
- 1.3.2 Bladder Cancer Treatment
- 1.3.3 Other
- 1.4 Market Analysis by Regions
- 1.4.1 North America (United States, Canada and Mexico)
- 1.4.1.1 United States Market States and Outlook (2014-2024)
- 1.4.1.2 Canada Market States and Outlook (2014-2024)
- 1.4.1.3 Mexico Market States and Outlook (2014-2024)
- 1.4.2 Europe (Germany, France, UK, Russia and Italy)
- 1.4.2.1 Germany Market States and Outlook (2014-2024)
- 1.4.2.2 France Market States and Outlook (2014-2024)
- 1.4.2.3 UK Market States and Outlook (2014-2024)
- 1.4.2.4 Russia Market States and Outlook (2014-2024)
- 1.4.2.5 Italy Market States and Outlook (2014-2024)
- 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- 1.4.3.1 China Market States and Outlook (2014-2024)
- 1.4.3.2 Japan Market States and Outlook (2014-2024)
- 1.4.3.3 Korea Market States and Outlook (2014-2024)
- 1.4.3.4 India Market States and Outlook (2014-2024)
- 1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
- 1.4.4 South America, Middle East and Africa
- 1.4.4.1 Brazil Market States and Outlook (2014-2024)
- 1.4.4.2 Egypt Market States and Outlook (2014-2024)
- 1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
- 1.4.4.4 South Africa Market States and Outlook (2014-2024)
- 1.4.4.5 Turkey Market States and Outlook (2014-2024)
- 1.4.1 North America (United States, Canada and Mexico)
- 1.5 Market Dynamics
- 1.5.1 Market Opportunities
- 1.5.2 Market Risk
- 1.5.3 Market Driving Force
2 Manufacturers Profiles
- 2.1 Bristol-Myers Squibb(BMS)
- 2.1.1 Business Overview
- 2.1.2 Checkpoint Inhibitors for Treating Cancer Type and Applications
- 2.1.2.1 Product A
- 2.1.2.2 Product B
- 2.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
- 2.2 Merck
- 2.2.1 Business Overview
- 2.2.2 Checkpoint Inhibitors for Treating Cancer Type and Applications
- 2.2.2.1 Product A
- 2.2.2.2 Product B
- 2.2.3 Merck Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
- 2.3 Roche
- 2.3.1 Business Overview
- 2.3.2 Checkpoint Inhibitors for Treating Cancer Type and Applications
- 2.3.2.1 Product A
- 2.3.2.2 Product B
- 2.3.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
3 Global Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)
- 3.1 Global Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Manufacturer (2017-2018)
- 3.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Manufacturer (2017-2018)
- 3.3 Market Concentration Rate
- 3.3.1 Top 3 Checkpoint Inhibitors for Treating Cancer Manufacturer Market Share in 2018
- 3.3.2 Top 6 Checkpoint Inhibitors for Treating Cancer Manufacturer Market Share in 2018
- 3.4 Market Competition Trend
4 Global Checkpoint Inhibitors for Treating Cancer Market Analysis by Regions
- 4.1 Global Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Regions
- 4.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Regions (2014-2019)
- 4.1.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Regions (2014-2019)
- 4.2 North America Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
- 4.3 Europe Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
- 4.4 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
- 4.5 South America Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
- 4.6 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
5 North America Checkpoint Inhibitors for Treating Cancer by Country
- 5.1 North America Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Country
- 5.1.1 North America Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Country (2014-2019)
- 5.1.2 North America Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Country (2014-2019)
- 5.2 United States Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
- 5.3 Canada Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
- 5.4 Mexico Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
6 Europe Checkpoint Inhibitors for Treating Cancer by Country
- 6.1 Europe Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Country
- 6.1.1 Europe Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Country (2014-2019)
- 6.1.2 Europe Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Country (2014-2019)
- 6.2 Germany Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
- 6.3 UK Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
- 6.4 France Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
- 6.5 Russia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
- 6.6 Italy Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
7 Asia-Pacific Checkpoint Inhibitors for Treating Cancer by Country
- 7.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Country
- 7.1.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Country (2014-2019)
- 7.1.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Country (2014-2019)
- 7.2 China Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
- 7.3 Japan Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
- 7.4 Korea Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
- 7.5 India Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
- 7.6 Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
8 South America Checkpoint Inhibitors for Treating Cancer by Country
- 8.1 South America Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Country
- 8.1.1 South America Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Country (2014-2019)
- 8.1.2 South America Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Country (2014-2019)
- 8.2 Brazil Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
- 8.3 Argentina Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
- 8.4 Colombia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
9 Middle East and Africa Checkpoint Inhibitors for Treating Cancer by Countries
- 9.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Country
- 9.1.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Country (2014-2019)
- 9.1.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Country (2014-2019)
- 9.2 Saudi Arabia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
- 9.3 Turkey Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
- 9.4 Egypt Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
- 9.5 Nigeria Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
- 9.6 South Africa Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2014-2019)
10 Global Checkpoint Inhibitors for Treating Cancer Market Segment by Type
- 10.1 Global Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Type (2014-2019)
- 10.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Type (2014-2019)
- 10.1.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Type (2014-2019)
- 10.2 PD-1 Inhibitors Sales Growth and Price
- 10.2.1 Global PD-1 Inhibitors Sales Growth (2014-2019)
- 10.2.2 Global PD-1 Inhibitors Price (2014-2019)
- 10.3 PD-L1 Inhibitors Sales Growth and Price
- 10.3.1 Global PD-L1 Inhibitors Sales Growth (2014-2019)
- 10.3.2 Global PD-L1 Inhibitors Price (2014-2019)
- 10.4 CTLA-4 Inhibitors Sales Growth and Price
- 10.4.1 Global CTLA-4 Inhibitors Sales Growth (2014-2019)
- 10.4.2 Global CTLA-4 Inhibitors Price (2014-2019)
11 Global Checkpoint Inhibitors for Treating Cancer Market Segment by Application
- 11.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2014-2019)
- 11.2 Melanoma Treatment Sales Growth (2014-2019)
- 11.3 Bladder Cancer Treatment Sales Growth (2014-2019)
- 11.4 Other Sales Growth (2014-2019)
12 Checkpoint Inhibitors for Treating Cancer Market Forecast (2019-2024)
- 12.1 Global Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate (2019-2024)
- 12.2 Checkpoint Inhibitors for Treating Cancer Market Forecast by Regions (2019-2024)
- 12.2.1 North America Checkpoint Inhibitors for Treating Cancer Market Forecast (2019-2024)
- 12.2.2 Europe Checkpoint Inhibitors for Treating Cancer Market Forecast (2019-2024)
- 12.2.3 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast (2019-2024)
- 12.2.4 South America Checkpoint Inhibitors for Treating Cancer Market Forecast (2019-2024)
- 12.2.5 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Forecast (2019-2024)
- 12.3 Checkpoint Inhibitors for Treating Cancer Market Forecast by Type (2019-2024)
- 12.3.1 Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Type (2019-2024)
- 12.3.2 Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Type (2019-2024)
- 12.4 Checkpoint Inhibitors for Treating Cancer Market Forecast by Application (2019-2024)
- 12.4.1 Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Application (2019-2024)
- 12.4.2 Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Application (2019-2024)
13 Sales Channel, Distributors, Traders and Dealers
- 13.1 Sales Channel
- 13.1.1 Direct Marketing
- 13.1.2 Indirect Marketing
- 13.1.3 Marketing Channel Future Trend
- 13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
- 15.1 Methodology
Summary:
Get latest Market Research Reports on Checkpoint Inhibitors for Treating Cancer . Industry analysis & Market Report on Checkpoint Inhibitors for Treating Cancer is a syndicated market report, published as Global Checkpoint Inhibitors for Treating Cancer Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024. It is complete Research Study and Industry Analysis of Checkpoint Inhibitors for Treating Cancer market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
